Canandaigua National Trust Co of Florida Acquires 1,104 Shares of Thermo Fisher Scientific Inc. $TMO

Canandaigua National Trust Co of Florida bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 3rd quarter, Holdings Channel reports. The firm bought 1,104 shares of the medical research company’s stock, valued at approximately $745,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. State Street Corp increased its holdings in Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after acquiring an additional 229,630 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $1,974,561,000. Bank of America Corp DE purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Thermo Fisher Scientific by 0.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,428,731 shares of the medical research company’s stock worth $1,407,328,000 after purchasing an additional 13,728 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMO. UBS Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the company from $540.00 to $730.00 in a research report on Tuesday, September 8th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Barclays increased their target price on Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Piper Sandler initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “overweight” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $633.13.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $4.39 during midday trading on Wednesday, hitting $660.97. 1,825,338 shares of the company traded hands, compared to its average volume of 2,251,859. The stock has a market cap of $244.39 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 2.83 and a beta of 0.87. The firm has a 50 day moving average of $622.56 and a 200-day moving average of $537.94. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $694.33.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Constructive outlook from investors: ClearBridge Investments highlighted Thermo Fisher’s strong third-quarter guidance, broadening demand across end markets and multi-year growth potential. The company’s innovation, acquisitions and diversified exposure to pharmaceutical, biotechnology and research customers are viewed as supporting its long-term outlook. Thermo Fisher Scientific Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
• Positive Sentiment: Expanded drug-development capabilities: At CPHI Milan, Thermo Fisher announced new and expanded manufacturing, clinical and drug-development solutions, including OSD Express. These offerings could improve customer efficiency and strengthen the company’s position as pharmaceutical companies outsource increasingly complex development and commercialization work. Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities
• Positive Sentiment: New clinical-research contract: Thermo Fisher’s PPD business will support Quantum BioPharma’s Phase 2 multiple-sclerosis trial. The agreement adds to Thermo Fisher’s clinical-research backlog and demonstrates demand for its contract research services, although the financial impact was not disclosed. Quantum BioPharma Signs Contract with Thermo Fisher Scientific
• Neutral Sentiment: Industry trends remain favorable: A market report projects continued growth in cell-based assays and high-content screening, driven by 3D assays, automation and immuno-oncology research. Thermo Fisher is listed among major participants, but the report does not announce company-specific financial results or contracts. Cell-Based Assay and High Content Screening Market Report
• Negative Sentiment: Recent volatility and valuation concerns: TMO recently fell sharply after hours and in the prior session, erasing roughly $10 billion in market value, likely reflecting profit-taking after reaching a new one-year high. Analysts also note macroeconomic and currency risks. With the stock trading at a premium earnings multiple, further gains may depend on continued execution and guidance upgrades. Is This the Right Time to Add TMO Stock to Your Portfolio?

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.